A recent study indicates that patients who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass much more quickly than those who halt traditional diet and exercise programs.
Findings released in a major medical journal shows that while obese individuals frequently drop about a fifth of their total mass while undergoing treatment, the weight comes back at an average rate of nearly a kilo each month upon discontinuation.
"People using such treatments need to be informed of the risk of rapid rebound weight gain when the medication concludes," cautioned researcher Dr. Susan Jebb.
This pace of regain implies a reversion to starting weight in about one and a half years.
Weighing Therapies
The study, which examined 37 of trials involving over 9,000 of patients, contrasted the outcomes of these new drugs with conventional dieting.
Scientists emphasize that people who shed pounds through dieting usually see a less rapid weight regain—around 0.1 kg a month—after stopping.
Understanding the Quick Rebound
Doctors suggest the mechanism of the jabs is key to understanding the amplified rebound.
GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.
"Long-term administration of the hormone levels several times higher than normal could lead to the system to produce less of its own natural hormone, and could diminish responsiveness to its effects," said Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this hormone supplement means hunger is no longer kept in check, making binge eating much more probable."
An Ongoing Condition?
Medical guidelines suggest the jabs for people with obesity-related medical conditions, alongside prescribed lifestyle changes.
Many experts contend that, considering the high risk of relapse, the therapy might need to be long-term.
This perspective is reinforced by drug manufacturers, who state that the findings "highlight the chronic nature of obesity," comparing it to managing diseases like high blood pressure.
Patient Accounts
People who have come off the jabs explain a intense resurgence of hunger.
"It was like something flipping and you become ravenous," said one woman.
The struggle is compounded if patients have not adopted lasting lifestyle or habit modifications during therapy.
Significant Use
Figures suggest that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with demand being substantial.
- Use is greater among females compared to males.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion obtain the medications through private healthcare rather than public health services.
Finally, clinicians stress that while GLP-1 drugs are potent agents for weight loss, they are not a standalone solution and lasting health benefits likely depends on combined lifestyle support.
